BRPI1014767A2 - métodos de tratamento de infecções bacterianas usando oritavancina - Google Patents

métodos de tratamento de infecções bacterianas usando oritavancina

Info

Publication number
BRPI1014767A2
BRPI1014767A2 BRPI1014767A BRPI1014767A BRPI1014767A2 BR PI1014767 A2 BRPI1014767 A2 BR PI1014767A2 BR PI1014767 A BRPI1014767 A BR PI1014767A BR PI1014767 A BRPI1014767 A BR PI1014767A BR PI1014767 A2 BRPI1014767 A2 BR PI1014767A2
Authority
BR
Brazil
Prior art keywords
oritavancin
methods
bacterial infections
treating bacterial
treating
Prior art date
Application number
BRPI1014767A
Other languages
English (en)
Inventor
Dario Lehoux
Geoffrey Mckay
Gregory Moeck
Sylvain Beaulieu
Thomas Parr Jr
Original Assignee
Targanta Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targanta Therapeutics Corp filed Critical Targanta Therapeutics Corp
Publication of BRPI1014767A2 publication Critical patent/BRPI1014767A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1014767A 2009-04-28 2010-04-26 métodos de tratamento de infecções bacterianas usando oritavancina BRPI1014767A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17345109P 2009-04-28 2009-04-28
PCT/US2010/032441 WO2010129233A2 (en) 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin

Publications (1)

Publication Number Publication Date
BRPI1014767A2 true BRPI1014767A2 (pt) 2016-04-19

Family

ID=43050709

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014767A BRPI1014767A2 (pt) 2009-04-28 2010-04-26 métodos de tratamento de infecções bacterianas usando oritavancina

Country Status (9)

Country Link
US (1) US9682061B2 (pt)
EP (1) EP2424559B1 (pt)
JP (1) JP2012525391A (pt)
CN (1) CN102573882A (pt)
AU (1) AU2010245097B2 (pt)
BR (1) BRPI1014767A2 (pt)
CA (1) CA2760159C (pt)
PT (1) PT2424559T (pt)
WO (1) WO2010129233A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009285564B2 (en) * 2008-08-30 2014-05-22 Melinta Therapeutics, Inc. Methods of treatment using single doses of oritavancin
BR112013001376A8 (pt) * 2010-07-20 2017-10-17 Sharp Kk dispositivo de distribuição de conteúdo, dispositivo de reprodução de conteúdo, sistema de distribuição de conteúdo, método de controle de um dispositivo de distribuição de conteúdo, programa de controle, e meio de gravação
NZ728401A (en) * 2014-07-17 2020-08-28 The Medicines Co High purity oritavancin and method of producing same
US10534895B2 (en) 2015-01-20 2020-01-14 Icpd Technologies, Llc System and method for ranking options for medical treatments
BR112018016715A2 (pt) * 2016-02-18 2019-02-19 Melinta Therapeutics, Inc. ?formulações de oritavancina?
CA3062570A1 (en) * 2017-05-22 2018-11-29 Insmed Incorporated Lipo-glycopeptide cleavable derivatives and uses thereof
KR102189125B1 (ko) * 2018-11-30 2020-12-10 주식회사 리얼타임테크 로그 수집 시스템 및 그 수집 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
CN1223378C (zh) 2000-05-02 2005-10-19 施万制药 含有糖肽抗生素和环糊精的药物组合物
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
ES2445941T3 (es) * 2006-09-25 2014-03-06 The Medicines Company Uso de oritavancina para la prevención y el tratamiento del ántrax
WO2008118784A1 (en) 2007-03-23 2008-10-02 Targanta Therapeutics Corp. Glycopeptide and lipoglycopeptide antibiotics with improved solubility
EA017564B1 (ru) 2007-09-12 2013-01-30 Тарганта Терапьютикс Корп. Способ ингибирования клостридиум диффициле введением оритаванцина
AU2009285564B2 (en) * 2008-08-30 2014-05-22 Melinta Therapeutics, Inc. Methods of treatment using single doses of oritavancin

Also Published As

Publication number Publication date
JP2012525391A (ja) 2012-10-22
CN102573882A (zh) 2012-07-11
WO2010129233A9 (en) 2011-02-03
WO2010129233A2 (en) 2010-11-11
CA2760159C (en) 2021-01-12
AU2010245097A9 (en) 2015-08-13
AU2010245097A1 (en) 2011-11-10
CA2760159A1 (en) 2010-11-11
US9682061B2 (en) 2017-06-20
PT2424559T (pt) 2024-04-30
EP2424559A1 (en) 2012-03-07
AU2010245097B2 (en) 2015-08-13
US20120035097A1 (en) 2012-02-09
EP2424559A4 (en) 2012-10-03
EP2424559B1 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
HK1247841A1 (zh) 苯並氧雜硼雜環戊二烯衍生物用於治療細菌感染
HK1225316A1 (zh) 治療病毒感染的方法
BRPI0910854A2 (pt) métodos de tratamento
EP2490530A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF BACTERIAL INFECTIONS
DK2982696T3 (da) Behandling af akut lymfoblastær leukæmi
PL2326287T3 (pl) Modułowe urządzenie rozprzestrzeniające do leczenia protetycznych zakażeń stawów
ZA201005798B (en) Treatment of microbial infections
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
HK1144794A1 (en) Devices for treatment of viral infections
SMT201600059B (it) Trattamento di infezioni da streptococco
BRPI1014767A2 (pt) métodos de tratamento de infecções bacterianas usando oritavancina
DK2473482T3 (en) Methods of treating orthomyxoviral infections
EP2473493A4 (en) METHODS OF TREATING POXVIRAL INFECTIONS
BRPI1010121A2 (pt) método de tratamento biológico
BRPI1014394A2 (pt) método de tratamento de vidro
ZA201204249B (en) Treatment of microbial infections
BRPI1011567A2 (pt) método de tratar fragilidade
CO6811849A2 (es) Tratamiento de infecciones bacterianas
GB0801768D0 (en) Treatment of microbial infections
GB0919711D0 (en) Treatment of viral infections
GB0913914D0 (en) Treatment of viral infections
GB0807781D0 (en) Treatment of bacterial infection
TH122542B (th) วิธีการและองค์ประกอบสำหรับการบำบัดภาวะกระดูก

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL